Curat Global LLC Trims Position in Amgen Inc. $AMGN

Curat Global LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 45.2% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,353 shares of the medical research company’s stock after selling 2,770 shares during the period. Amgen accounts for approximately 1.2% of Curat Global LLC’s portfolio, making the stock its 16th largest position. Curat Global LLC’s holdings in Amgen were worth $1,097,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Brighton Jones LLC raised its holdings in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after buying an additional 114 shares during the last quarter. Schnieders Capital Management LLC. raised its holdings in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC raised its holdings in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after purchasing an additional 416 shares in the last quarter. Finally, Ieq Capital LLC raised its holdings in Amgen by 5.1% during the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after purchasing an additional 2,611 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Trading Up 1.8%

Shares of Amgen stock opened at $337.42 on Friday. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market cap of $182.10 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 3.33 and a beta of 0.44. The company has a 50-day moving average of $345.86 and a two-hundred day moving average of $344.41.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the company posted $4.90 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen’s dividend payout ratio (DPR) is 70.15%.

Analyst Upgrades and Downgrades

AMGN has been the subject of several analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Morgan Stanley set a $332.00 price target on shares of Amgen in a report on Friday, May 1st. Piper Sandler cut their price target on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a report on Thursday, May 14th. Barclays initiated coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Finally, Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $355.19.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s xaluritamig prostate cancer trial is advancing, which supports the company’s long-term pipeline narrative and could improve investor confidence in future oncology revenue. Amgen Advances Xaluritamig Trial in Hard-to-Treat Prostate Cancer
• Positive Sentiment: Analysts remain constructive on Amgen despite a small target cut, with Piper Sandler reiterating an Overweight rating and other coverage pointing to pipeline strength and sales growth. Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth
• Positive Sentiment: Argus lowered its price target to $375 from $400 but kept a Buy rating, reinforcing the view that Amgen still has upside from current levels. Argus adjusts price target on Amgen to $375 from $400, maintains Buy rating
• Neutral Sentiment: Amgen was included in a broad report on the late-stage chronic kidney disease market, which is more of an industry overview than a company-specific catalyst. Late-Stage Chronic Kidney Disease Market Analysis Report 2026-2036
• Negative Sentiment: Amgen’s rare-disease drug Tavneos faced new warning-related scrutiny in Japan after patient deaths, though regulators later allowed new patients to be prescribed the drug again; this may still weigh on sentiment because it highlights safety risk. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths
• Negative Sentiment: A broader Senate bill on maternal health could affect large pharma and biotech companies indirectly through future research, surveillance, and policy changes, but it is not an immediate Amgen-specific driver. New Bill: Senator Elizabeth Warren introduces S. 4550: Maternal Health Pandemic Response Act

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.